Immunome, Inc. Cash and Cash Equivalents
Immunome, Inc. (IMNM) had Cash and Cash Equivalents of $217.71 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-11
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $217.71M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $582.69M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $653.48M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $272.64M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $217.71M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $582.69M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $653.48M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $272.64M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $143.88M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $257.61M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $143.35M 10-K · filed 2026-03-03 |
| 2024-09-30 | $155.57M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $165.33M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $269.72M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $98.68M 10-K · filed 2025-03-19 |
| 2023-09-30 | $90.64M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $38.42M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $44.42M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $20.32M 10-K · filed 2024-03-28 |
| 2022-09-30 | $27.08M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $34.65M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $42.88M 10-Q · filed 2023-05-05 |
| 2021-12-31 | $49.23M 10-K · filed 2023-03-16 |
| 2021-09-30 | $56.24M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $59.83M 10-Q · filed 2022-08-05 |
| 2021-03-31 | $36.28M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $39.77M 10-K · filed 2022-03-28 |
| 2020-09-30 | $6.74M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $9.79M 10-Q · filed 2021-08-16 |
| 2019-12-31 | $2.54M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |